Elite Pharmaceuticals Profit Margin

The latest profit margin for ELTP is 40.19% as of June 2026. That compares with -10.26% in the prior-year period — up 491.8% year over year. That is above the Healthcare sector average of 21.34%. Investors often review this figure alongside Elite Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ELTP's profit margin moved from -10.26% to 40.19% — a 491.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Elite Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ELTP currently prints 40.19% for profit margin, while the sector average sits near 21.34%. That is roughly 88.4% above the sector mean. Large gaps often invite a closer look at Elite Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Elite Pharmaceuticals converts resources into returns. At 40.19%, ELTP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -10.26% in the prior-year period — up 491.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ELTP's profit margin (40.19%), review year-over-year change from -10.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.